When redo-transcatheter aortic valve replacement (TAVR) is not enough: self-expanding TAVR explant and the next frontier of lifetime valve management
a practical, rather than theoretical, issue (3). Reintervention after TAVR remains uncommon on a per-patient basis, yet the absolute number is rising: in the FRANCE 2 and FRANCE TAVI registries, cumulative reintervention reached 1.7% at 8 years, and in a recent Centers for Medicare & Medicaid Services (CMS) analysis of...